<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02216266</url>
  </required_header>
  <id_info>
    <org_study_id>DELIcu</org_study_id>
    <secondary_id>2012-004082-41</secondary_id>
    <nct_id>NCT02216266</nct_id>
  </id_info>
  <brief_title>Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery</brief_title>
  <official_title>Monocenter, Double Blind, Randomised, Placebo Controlled Study to Evaluate Physostigmine for the Treatment of Delirium in Perioperative Intensive Care Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. Bertram Scheller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Franz Köhler Chemie GmbH (study medication and labeling)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation if physostigmine reduces symptoms in patients who has developed a delirium in
      Intensive care after a surgery
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of vigilance or symptoms of the delirium measured by Richmond Agitation Sedation Score (RASS)</measure>
    <time_frame>baseline to 48 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of weaning time at mechanical ventilator of patients with symptoms of delirium</measure>
    <time_frame>baseline to 48 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the spontaneous EEG and auditory evoked potentials</measure>
    <time_frame>baseline to 48 hours after administration</time_frame>
    <description>for the spontaneous EEG, we expect a shift in the frequency characteristics, measure is the spectrogram, more precisely the amplitude per frequency (band) and the phase information derived via Fourier Transform and Wavelet transformation
The paradigm of the auditory stimulation is a roving paradigm (Science 13 May 2011:
Vol. 332 no. 6031 pp. 858-862 DOI: 10.1126/science.1202043
•Report Preserved Feedforward But Impaired Top-Down Processes in the Vegetative State Melanie Boly1,2,*, Marta Isabel Garrido2, Olivia Gosseries1, Marie-Aurélie Bruno1, Pierre Boveroux3, Caroline Schnakers1, Marcello Massimini4, Vladimir Litvak2, Steven Laureys1, Karl Friston2) Measures will be differences in the mismatch negativity and in the phase synchronization between electrodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of the variability of heart rate</measure>
    <time_frame>baseline to 48 hours</time_frame>
    <description>heart rate variability is a dimensionless parameter, assessing the variability of the heart rate from ECG measures (Heart Rate Variability Conny M. A. van Ravenswaaij-Arts, MD; Louis A. A. Kollee, MD, PhD; Jeroen C. W. Hopman, MSc; Gerard B. A. Stoelinga, MD, PhD; and Herman P. van Geijn, MD, PhD [+-] Article and Author Information
Ann Intern Med. 1993;118(6):436-447. doi:10.7326/0003-4819-118-6-199303150-00008 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in development of muscular force</measure>
    <time_frame>baseline up to 48 hours</time_frame>
    <description>muscular force is measured with a force gauge, measured in [Newton]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Adverse events</measure>
    <time_frame>baseline to 4 weeks after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Suspected Delirium After Elective or Emergency Heart Surgery</condition>
  <condition>CAM-ICU Diagnosed Delirium</condition>
  <arm_group>
    <arm_group_label>Physostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physostigmine</intervention_name>
    <arm_group_label>Physostigmine</arm_group_label>
    <other_name>Anticholium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sodium Chloride solution</intervention_name>
    <arm_group_label>Sodium Chloride solution</arm_group_label>
    <other_name>NaCl solution as Placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both genders aged &gt; 18 years, &lt; 85 years of ICU C1 after elective or
             emergency heart surgery with or without extracorporeal circulation (heart-lung machine
             and/or extracorporeal membrane oxygenation), with suspected delirium. (May be
             suspected if a patient does not show adequate improvement of vigilance 24 h after
             adequate reduction or stop of sedative medicine)

          -  Patients (&gt;18a, &lt;85a) with CAM-ICU diagnosed delirium

          -  Patients of legal capacity and patients with appointed representative

        Exclusion Criteria:

          -  Asthma

          -  hypersensitivity against Physostigmine salicylate, Sodium metabisulfite, Nitrogen

          -  gangrene mechanical obstipation

          -  mechanical urinary retention

          -  Dystrophia myotonica

          -  Depolarization block after depolarising muscle relaxants

          -  Intoxications with &quot;irreversibly acting&quot; cholinesterase inhibitors

          -  closed head trauma

          -  obstructions at gastro-intestinal tract and at urinary tract

          -  neurological diseases

          -  left ventricular ejection fraction &lt; 40%

          -  Simultaneous Participation in other clinical trials or participation ind other
             clinical trials in the last 30 days

          -  untreated coronary heart disease

          -  wish to have children, pregnancy or nursing

          -  patients with addictive disorder in medical history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram Scheller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy of Goethe-University Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertram Scheller, MD</last_name>
    <email>bertram.scheller@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessia</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bertram Scheller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2013</study_first_submitted>
  <study_first_submitted_qc>August 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2014</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>PD Dr. Bertram Scheller</investigator_full_name>
    <investigator_title>PD MD Bertram Scheller</investigator_title>
  </responsible_party>
  <keyword>Delirium</keyword>
  <keyword>CAM-ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Physostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

